Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Merck
AstraZeneca
Mallinckrodt
Harvard Business School

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR DECITABINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Decitabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000623 ↗ Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed National Heart, Lung, and Blood Institute (NHLBI) 2000-07-01 The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 ↗ Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed Thalassemia Clinical Research Network 2000-07-01 The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 ↗ Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed HealthCore-NERI 2000-07-01 The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 ↗ Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed New England Research Institutes 2000-07-01 The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00002831 ↗ Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Completed National Cancer Institute (NCI) Phase 1/Phase 2 1995-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002831 ↗ Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Completed M.D. Anderson Cancer Center Phase 1/Phase 2 1995-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Decitabine

Condition Name

Condition Name for Decitabine
Intervention Trials
Acute Myeloid Leukemia 92
Myelodysplastic Syndrome 55
Myelodysplastic Syndromes 53
Untreated Adult Acute Myeloid Leukemia 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Decitabine
Intervention Trials
Leukemia 200
Leukemia, Myeloid, Acute 187
Leukemia, Myeloid 178
Myelodysplastic Syndromes 154
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Decitabine

Trials by Country

Trials by Country for Decitabine
Location Trials
China 86
Canada 56
Germany 47
Italy 44
France 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Decitabine
Location Trials
Texas 115
New York 78
California 62
Ohio 59
Maryland 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Decitabine

Clinical Trial Phase

Clinical Trial Phase for Decitabine
Clinical Trial Phase Trials
Phase 4 6
Phase 3 35
Phase 2/Phase 3 15
[disabled in preview] 336
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Decitabine
Clinical Trial Phase Trials
Completed 140
Recruiting 91
Terminated 49
[disabled in preview] 113
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Decitabine

Sponsor Name

Sponsor Name for Decitabine
Sponsor Trials
National Cancer Institute (NCI) 94
M.D. Anderson Cancer Center 53
Eisai Inc. 32
[disabled in preview] 54
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Decitabine
Sponsor Trials
Other 424
Industry 218
NIH 104
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
AstraZeneca
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.